Good afternoon, everyone, and thank you for participating in today's conference call to discuss Research Solutions Financial and Operating Results for its Fiscal Fourth Quarter and Full-Year Ended June 30, 2022. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, John Beisler, Investor Relations.

Thank you, Ariel, and good afternoon, everyone. Thank you for joining us today for Research Solutions' fourth quarter and full-year fiscal 2022 earnings call. On the call with me today are Roy W. Olivier, President and Chief Executive Officer and Bill Nurthen, Chief Financial Officer. After the market closed this afternoon, the Company issued a press release announcing its results for the fourth quarter and full-year fiscal 2022. The release is available on the Company's website researchsolutions.com. Before Roy and Bill begin their prepared remarks, I would like to remind you that some of the statements made today will be forward-looking and made under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those expressed or implied due to a variety of factors. We refer you to Research Solutions' recent filings with the SEC for a more detailed discussion of the risks that could impact the Company's future operating results and financial condition. Also on today's call, management will reference certain non-GAAP financial measures, which we believe provide useful information for investors. A reconciliation of those measures to GAAP measures is included in the earnings press release issued this afternoon. Finally, I would like to remind everyone this call being recorded and made available for replay via a link on the Company's website. I would now like to turn the call over to Roy W. Olivier. Roy?

Thank you, John, and thanks to everyone joining for our fourth quarter and fiscal 2022 results. Before I get into specifics about our performance versus plan, I want to quickly recap some of our results that we accomplished during the fiscal year. During FY2022, we sold 180 net new customers, resulting in net ARR growth of over $2 million for the first time. Our customer acquisition costs or CAC, a measure of our sales efficiency, ran at about 13 months slightly over our target of 12. Our lifetime value to CAC also remains very strong at approximately 9x our CAC. Both of these measurements put us in the better or best category as defined by Bessemer Venture Partners SaaS guardrails and indicate that we should continue to invest in growing the top line, which we plan on doing. Renewal rates remain strong in the high 90s and our net renewal rates ran over 110% for the year and stand at an internal record on a trailing 12-month basis. We also started measuring Net Promoter Score or NPS during the year and our average NPS score for the year is 63, well above the 2022 SaaS company average of 41. Both the renewal rates and the NPS score underscore the value we are delivering to our customers and will remain key metrics influencing our strategy moving forward. During the full fiscal year, we made tremendous progress related to our product strategy, which I will cover in more detail later in the call. We released significant upgrades to the Article Galaxy platform, including pivoting to a good, better and best version of Article Galaxy. We also released Article Galaxy References, both a standard and pro version of the software. References is a reference manager application that will significantly improve the value proposition of the Article Galaxy platform to our users. Finally, we are about to release a new product called Curedatis, which is a regulatory compliance tool that is integrated with Article Galaxy. Curedatis is a pharmacovigilance product intended to help our customers collect, detect, assess, monitor and prevent adverse effects with pharmaceutical and other products. Pharmacovigilance is required in several vertical markets and countries we serve and is a manual process today in many cases. This product automates the process and integrates with Article Galaxy to help our customers search, identify and acquire scientific articles that are related to that process. I'd like to pass the call over to Bill to walk through our fiscal fourth quarter and 2022 year-end financial results in detail, and then I'll wrap up with some more comments related to our products, strategy and M&A. Bill?

Thank you, Roy, and good afternoon, everyone. I will begin with a recap of our results for the fourth quarter of fiscal 2022. Total revenue was $8.6 million, a 4.2% increase from the fourth quarter of fiscal 2021. Our platform subscription revenue increased 32% to $1.9 million, primarily driven by a net increase in platform, annual recurring revenue bookings and deployments from last year, including a new company record of $573,000 in incremental ARR bookings in the fourth quarter, along with 53 net new deployments. We ended the quarter with $7.9 million in annual recurring revenue, up almost 8% sequentially and 35% year-over-year, reflecting our continued sales and upselling efforts and low churn of existing platform subscribers. Please see today's press release for how we define and use annual recurring revenue in other non-GAAP terms. Our transaction revenue decreased slightly to $6.7 million from $6.8 million in the fourth quarter of 2021. Our total active customer count for the quarter was 1,213, a net increase of 81 from the same period a year-ago and 20 customers from the third quarter of fiscal 2022. The sequential increase was primarily due to more corporate customers. I will note that while the trend regarding transaction revenue has been slightly down, the year-over-year performance did improve through the fiscal year after a steep drop-off in the first quarter of fiscal 2022. I will talk more about what I think this means for our upcoming fiscal Q1 and fiscal 2023 later. Turning to gross margin. As we continue our mix shift to platform revenue, we continue to see corporate gross margins move up into the right. In addition, as noted in our press release, we reached an important milestone for the company as this was the first quarter in which the gross profit from our…

Thank you, Bill. About 18 months ago, I described the major priorities of the business as follows: First, we were going to focus on accelerating growth. Second, we were going to review the business with an eye toward ensuring it can support that growth. Third, we were going to update and roll out our vision, mission and values to our base of employees. And fourth, we were going to review and update the IR plan to expand the shareholder base and analyst coverage. I'd like to take a few minutes and provide an update for each of those items. Regarding accelerating growth are previously communicated that we wanted to accelerate topline growth organically and via acquisitions. That organic growth was intended to be the result of enhancing our sales force and a revamped product strategy. As a result, we did expand our sales force, upgraded our prospecting process and CRM and other related systems and improved the process associated with our upsell and renewal teams. This resulted in 180 net new platform deployments in FY2022 and over $2 million in net ARR growth both records. Our platform growth rate for the year was 32% slightly better than FY2021. That said, it did remain 32% on a larger base versus declining for the previous four years. On the product side, we delivered big time. We pivoted to a good, better and best version of Article Galaxy. We created and released two versions of a reference manager application called References and References Pro and we will shortly release a pharmacovigilance product. Most of these updates were released in Q4, one in Q1 of FY2023 and line us up well as we seek to continue record new deployments and renewal rates in FY2023. Regarding acquisitions, the results have been disappointing. In the first…

Thank you. We will now begin the question-and-answer session. [Operator Instructions] Our first question – go ahead.

I'm sorry. I do have three questions via email. Would you like me to do that now or wait?

By all means.

I have a question confused about comments, our repricing initiatives as ASP at quarter-end Q4 seen below ASP for Q4 2021? That is true. The ASP is lower. And as a reminder, our ASP is heavily influenced by the first customers that signed up for the platform that are by far the largest customers. Customers that have hundreds – in some cases, several hundred seats, a lot of the 180 deployments we're doing now and a lot of our focus from a sales and marketing perspective is on SMB where that ASP is lower. So we can expect to see 6,000 to 8,000 lower ASPs on new sales in the SMB space versus our corporate ASP number, which is between 10,000 and 11,000. The second question I got…

Roy?

Yes.

If I can just add real quickly to that, too, while we are – we did do some pricing initiatives on the platform, a lot of what I was referencing with respect to pricing initiatives as things that we're doing on the transaction side of the business to improve margins there.

Second question I got was nice growth in deferred revenue. Is this mostly in platforms? Can you please talk about seasonality expected in deferred revenue? Bill I'll turn that over to you.

Yes. It definitely has something to do with seasonality and also having a record bookings quarter for the fourth quarter, obviously with the platform, everything that we build, there's an annual upfront payment. And so when we have a strong quarter, we put out a lot of annual bills that do drive the deferred revenue balance up. Typically from a seasonality standpoint, you will see that deferred revenue drop in Q1, as we sort of typically have our strongest quarters in the back half of the year. And so I would expect the deferred revenue balance to come down by the end of Q1.

Okay. Why don't we open it up for questions and then I have a third one, but we'll give some of the folks a chance.

Certainly. Our first question comes from Allen Klee of Maxim Group. Please go ahead.

Good afternoon. I wanted to – could you talk a little about how Galaxy Scholar has performed and your thoughts about how your expectations on that? And then secondly, with your new product, Curedatis, how you think about the launch – when this is – how you're thinking about the ramp up of what you're planning to and how long this could potentially take to become material? Thank you.

Yes. Good questions. Article Galaxy Scholar, I think, has been disappointing in terms of customer take rate. In other words, we're definitely – it's harder to sell when Article Galaxy is. However, once they do take it, it produces a pretty nice jump in transactional revenue. So we're actually reevaluating our pricing and sales strategy on the product, and we will likely split it into two versions. Right now it's a single version and it's paid-only. We're going to split it into a freemium version, which will drive transaction revenues positive and a paid version that delivers some of the high value that libraries are willing to pay for. But the ARPU on the product will continue to be well below Article Galaxy and we're going to have to see in the coming months, whether or not we can get the traction that we hope to get by splitting it into a freemium and premium product. In terms of your second question on Curedatis, it will launch in October. We have very conservatively budgeted for its sales in FY2023 is a little bit as a result of the – what – the surprise on Article Galaxy Scholar, but we do expect it to generate a few hundred thousand in revenue. You asked me, I believe in the last call, the TAM and SAM for that product. I will tell you now that pharmacovigilance as an industry has a TAM of about $650 million worldwide. The SAM, the serviceable market in the U.S. and Europe, which we serve, is about $435 million. However – and this is a really big, however, all capital letters underlined, we are releasing the MVP, which is the minimum viable product, the release one that we will continue to add to over time, but we want to see it be successful first. So we think the TAM for the MVP or service addressable market or adjusted, whatever you want to call it, is in the tens of millions. But as we launch this product, if we see traction with it, we're going to make the changes to expand its applicability from a vertical perspective. It already meets the country requirements, specifically the U.S. and Europe regulations. So we'll add capability, so that's applicable to other industries outside of pharmaceutical or outside of medical devices and it's an exciting product that does integrate with Article Galaxy, and we're very bullish on it, but we're being conservative in terms of the operating plan forecasts in FY2023. Go ahead. Next question.

That's great. Yes. Could I follow-up – a question that I had was – I apologize, I just missed something, when you were talking about guidance and first quarter, and you talked a little bit about for fiscal first quarter, you said something about 5%, but then you also said double-digit. What were the difference between those two numbers?

Yes. That's just the range - sorry, Roy, if I cut you off. That's just the range of the outcomes we are pursuing right now. In other words, with some of the early returns that we've seen so far, we think top line growth will be somewhere over 5%, potentially up to 10%.

Great. And my last question, and then I'll get back in the queue to let other people. Is in the platform segment, you think it can grow at the same rate. When you say same rate, are you talking absolute revenues or year-over-year percentage type rates?

Percentage.

Yes.

Percentage. Okay, great. Thank you so much. Congrats on the quarter.

Our next question comes from Richard Baldry of ROTH Capital. Please go ahead.

Thanks. On the pharmacovigilance product, can you talk a bit about the sales model for that? How similar it will be? Whether the buyer – the end buyer, not just the company itself, but the person making the purchasing decision is someone you've dealt with before. Whether – if you have some early positive returns on that? Would that or could that warrant its own standalone sales team, just sort of flesh out the go-to-market there? Thanks.

Yes. I think those are all great questions. The buyer, in some cases, is the same business decision maker. And what I mean by that is there some regulatory affairs capability and depending on the size of the company that we're selling to, that would be the buyer of both products. However, we also have a pretty good percentage of our customer base, where it is a separate buyer. However, it is applicable to almost every customer that's on the platform today or a pretty big percentage of the platform customers today. So we certainly know typically at least an executive or a librarian that's responsible for the research side of the business that can introduce us to the regulatory affairs folks that would typically look at a pharmacovigilance product. We are planning today on selling it through our current sales force. However, if we get the traction that we hope to see, then I think we'll need to evaluate whether we want to bring on a dedicated sales force for that product. We have had several development partners that – and these are companies that partly own Article Galaxy that have helped us through the development process. Many of those companies are going through the purchasing process now to add it to their subscription. So we're optimistic about it, but I also don't want to overcommit.

Okay. And could you talk a little bit more about the severance repositioning sort of efforts? How complete you think that is? Is there more strategic sort of long-term thinking still underway that could result in any more sort of repositioning throughout 2023? Or do you feel like you're in a pretty good stance as you exit the year?

Well, I think our intent was certainly to do it once at the end of the year and not have any additional expenses this year. That said, there are some surprising at least to me, severance requirements in Mexico, which are much more generous than the ones in the United States and even many countries in Europe. And we're also – if we feel like we need to make a change because of strategic shift or whatever, we will go ahead and do that and we'll communicate what the severance impact is, but our intent was to do it once and not have anymore.

And I know in the past, you were inquisitive at your prior firm, so maybe under this sort of infrastructure you've got at Research Solutions, could you talk about what your approach to M&A would be maybe in terms of funding, how comfortable you are with drawing cash down on the balance sheet, how important you think equity components to newly acquired entities are? Just to give us sort of a backdrop or how to think about what M&A might look like when it comes to paying for those deals? Thanks.

Yes. In our last assignment, Bill and I ran a fairly significant EBITDA margin, so we were able to do some deals. We would able to do some portion of a deal with debt. So we would typically borrow 2.5x, 3x EBITDA of the new combined organization, and then use some cash and occasionally use stock. Although we didn't do that very often and also use seller notes. So I would expect a similar playbook here, although we cannot use debt until we start generating some material amount of EBITDA, I will say, I'm not crazy about giving away stock, especially when we're at under $2 a share. So I'm open to seller notes. I'm open to using a significant percentage of the cash on the balance sheet because we will be producing cash going forward, but we're not going to use all of it. We'll use some portion of it to get a deal done.

Then your ARR growth has been pretty strong. Could you talk about – and this would be my last question. Talk about how high a quota attainment rate you're getting? Sort of curious about the capacity you have in sales to keep up or expand from sort of the win rates dollar, win rates you've been having in fiscal 2022 as we look forward?

Yes. Last year, I believe – and Bill, can correct me, I believe we had every, new, new hunter person hit their quota that had been here for a while. They weren't in ramp. And I believe we had most of our upsell renewal people hit their numbers as well. So they are hitting their quotas. To answer your broader question, we don't have a capacity problem. We have a filling the top of the funnel problem. In other words, we can book probably five to 10 more appointments per week per salesperson. And we would expect to continue to close those at a similar close rate that we have now, which is about a third of those typically closed. So for us, it's filling the top of the funnel, not capacity with the existing team. And then obviously part B of that is we'll feel comfortable that we can expand the existing team as we need to.

Great. Thanks for taking my questions and congrats on a good quarter.

Thanks. And related to one of your questions, one that came in via email was other than 275 in severance, are there other one-time costs in R&D and G&A? And are you finished rolling out various upgrades? Do these costs decline? The answer is yes. There is some other one-time costs in FY2022 related to the CRM project, related to the aforementioned accounting upgrade and a few other things. We didn't define those. There is actually some one-time R&D costs related to the development of Curedatis, where we used the third party to help us get launched. But I don't think we've defined those or communicated them externally. Bill, is there anything you want to add to that?

No. I think you touched on the key things. It was some outsourced development for Curedatis and some of the internal system development that we've been talking about that was also impacting this particular quarter.

Okay. Next question, operator?

Our next question is a follow-up from Allen Klee of Maxim Group. Please go ahead.

Yes. Thank you. For transaction revenue, can you remind us is there any seasonality in the quarters typically in that business?

Bill will give you the exact numbers, but there is some – Q1 is typically our slowest quarter from a platform perspective. The transaction business, there is some seasonality, which Bill can comment to, but there's also just external factors. Like when the war in Ukraine started, everybody stopped doing research for a week or two, probably paid attention to what was going on over there. COVID obviously had a big impact on researchers, so that there's other events that impact that that don't have anything to do with seasonality. And then Bill, do you want to comment on the seasonality question?

Yes. Typically, Q1 and Q2 of our fiscal year are typically the lowest quarters that we see for transactions and they can be relatively stable. But as Roy mentioned, some things do impact that potentially the given quarter. Q3 is typically always our best transaction quarter. So typically we see a nice jump in Q3 and then a flattening out to down in Q4. And so I would expect that seasonality will likely hold again as we move into this fiscal year.

Thank you. My last – I was just trying to do a sanity check on like estimates. And I didn't catch what you said for how many people renew. You said something about 90%. I don't know if it was 90% or high 90% because what I was trying to think of is if I took this quarter's revenue, and then I took your incremental ARR that you add, and if I assume you recognized half of that quarterly or if you kept that ARR at that same level for four quarters next year, and you recognized half of it as revenue on top of it, I come up with a number of – for revenue, but then I think I have to reduce it for penetration or customers that you'd lose. So I was wondering if this is a reasonable way to think about kind of your outlook.

Bill, do you want to take that?

Yes. I think that you could do that, but yes, you'd have to do factor in those that would churn out. I think the easier way to kind of think about it is, what revenue rate are we growing at and what is the sort of forward ARR growth rate? So we said on the call at the end of this quarter, the forward ARR growth rate was just under 35% and then typically our recognized revenue has been growing 32%. And so I would view that as a sort of a bias upwards a little bit on the growth rate that is we've been realizing, which is the 32%, but that's something that I would sort of continue to monitor as we continue to post through the year is what is the recognized rate and then what are we seeing in the forward ARR growth rate.

Great. Thank you so much.

There are currently no further questions from the phone lines. I would like to turn the conference back over to Roy Olivier.

Thank you, and thanks everyone for joining us on our call today. We will be attending the LD Micro Main Event in October. And for more information about this event, please contact LD Micro. We look forward to speaking to you in November to discuss our first quarter fiscal 2023 results. And we hope you have a great day.

This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.